ScreenerHero

AUTL Autolus Therapeutics plc

NAS · US · Healthcare · Biotechnology · autolus.com
1.810USD+1.12%Mkt Cap: 481.75M $P/E: —

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap481.75M USD
Enterprise Value642.61M USD
Revenue (TTM)117.39M USD
Gross Profit-20.98M USD
Net Income (TTM)-287.53M USD
Revenue/Share0.44 USD
Last Price1.810 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees752
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.86
PEG—
EV/EBITDA-2.72
EV/Revenue5.47
P/S4.06
P/B6.37
EPS (TTM)-1.04
EPS (Forward)-0.63
52W Range
1.17545% of range2.580
52W High2.580 USD
52W Low1.175 USD
Profitability
Gross Margin-27.83%
Oper. Margin-95.95%
EBITDA Margin-201.53%
Profit Margin-381.40%
ROE-161.42%
ROA-48.81%
Growth
Revenue Growth118.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-283.57M USD
CapEx (TTM)27.13M USD
FCF Margin-171.39%
FCF Yield-41.76%
Net Debt166.18M USD
Net Debt/EBITDA-0.70
Balance Sheet
Debt/Equity0.40
Current Ratio4.89
Quick Ratio4.06
Book Value/Sh0.28 USD
Cash/Share0.76 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.725 USD
Upside (mean)+382.0%
Target Range5.000 USD – 11.00 USD
5.000+382.0% to mean11.00
# Analysts8
Ownership
Shares Out.266.16M
Float102.92M
Insiders18.09%
Institutions63.43%
Short Interest
Short Ratio3.9d
Short % Float4.82%
Short % Out.3.13%
Shares Short8.33M
Short (prev mo.)10.48M
Technical
SMA 502.033 (-10.9%)
SMA 2001.674 (+8.1%)
Beta2.14
S&P 52W Chg16.45%
Avg Vol (30d)1.91M
Avg Vol (10d)1.63M
Technical Indicators
RSI (14)41.6
MACD-0.0646
MACD Signal-0.0479
MACD Hist.-0.0167
BB Upper2.078 USD
BB Middle1.908 USD
BB Lower1.738 USD
BB Width17.81%
ATR (14)0.1104 USD
Vol Ratio (20d)0.95x